TD Asset Management Inc Cuts Position in Medtronic PLC $MDT

TD Asset Management Inc trimmed its position in shares of Medtronic PLC (NYSE:MDT) by 4.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,117,213 shares of the medical technology company’s stock after selling 56,771 shares during the period. TD Asset Management Inc owned approximately 0.09% of Medtronic worth $106,403,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Riverbend Wealth Management LLC raised its stake in Medtronic by 3.2% during the third quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company’s stock valued at $332,000 after purchasing an additional 107 shares in the last quarter. Holistic Financial Partners raised its position in shares of Medtronic by 3.0% during the 3rd quarter. Holistic Financial Partners now owns 3,697 shares of the medical technology company’s stock valued at $352,000 after buying an additional 109 shares in the last quarter. Wynn Capital LLC lifted its holdings in shares of Medtronic by 2.4% in the 3rd quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock valued at $442,000 after acquiring an additional 110 shares during the last quarter. Meridian Investment Counsel Inc. grew its position in Medtronic by 0.4% in the third quarter. Meridian Investment Counsel Inc. now owns 28,268 shares of the medical technology company’s stock worth $2,692,000 after acquiring an additional 110 shares in the last quarter. Finally, Saxony Capital Management LLC grew its position in Medtronic by 3.8% in the third quarter. Saxony Capital Management LLC now owns 3,046 shares of the medical technology company’s stock worth $290,000 after acquiring an additional 112 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s Diabetes unit, MiniMed, has priced an IPO targeting up to $784M (28M shares at $25–$28). The move advances the planned spin‑off and could unlock value for Medtronic shareholders by creating a focused, public diabetes company. Medtronic’s MiniMed prices IPO at up to $784M
• Positive Sentiment: Medtronic launched the MiniMed Go Smart MDI system with the Simplera sensor commercially across EMEA — the first app to combine InPen smart‑pen data with Simplera sensor data. Europe rollout expands MiniMed’s addressable market and supports recurring revenue from diabetes consumables and services. Medtronic begins EMEA commercial launch of MiniMed Go Smart MDI system with Simplera sensor
• Positive Sentiment: Medtronic also reported FDA clearance for its Stealth AXiS spine surgical system (noted in coverage of its portfolio reshaping), which could boost its spine franchise and procedure‑related revenue over time. Medtronic Reshapes Portfolio With MiniMed IPO And Stealth AXiS Approval
• Neutral Sentiment: MiniMed’s IPO roadshow is underway with an investor presentation and expected pricing timeline; investors will watch subscription demand and final pricing for signals about appetite for diabetes assets. MiniMed announces launch of IPO roadshow
• Neutral Sentiment: Reports cite a potential MiniMed valuation near $7.9B—valuation and the amount Medtronic retains (or sells) will determine the magnitude of balance‑sheet and EPS impact. Medtronic’s diabetes unit MiniMed eyes $7.9 billion valuation in US IPO
• Neutral Sentiment: Analyst commentary (e.g., “inflection trade” coverage) suggests investors see a potential turnaround if new product approvals and the portfolio split accelerate growth; this is sentiment‑driven and depends on execution. Why the Medtronic (MDT) ‘Inflection Trade’ is Back On
• Negative Sentiment: Spin‑off/IPO risk — separating MiniMed reduces Medtronic’s near‑term revenue base and could introduce one‑time costs, dilution or changes to reported EPS and margin metrics; some investors may discount MDT shares until the post‑split capital allocation is clear. Medtronic’s diabetes business MiniMed looks for $784m in US IPO
• Negative Sentiment: Industry competition and lobbying developments (e.g., new diabetes sector leadership) highlight competitive pressure in diabetes tech that could affect market share and pricing over time. AdvaMed names Jake Leach as chair of diabetes sector

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on MDT. TD Cowen reaffirmed a “buy” rating on shares of Medtronic in a research note on Friday, November 14th. Piper Sandler restated a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. Wells Fargo & Company started coverage on shares of Medtronic in a research report on Friday, January 30th. They set an “overweight” rating and a $114.00 price objective on the stock. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Royal Bank Of Canada upped their price target on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.84.

Medtronic Trading Down 0.0%

Shares of NYSE MDT opened at $96.71 on Thursday. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The firm has a market cap of $123.98 billion, a PE ratio of 26.94, a price-to-earnings-growth ratio of 2.43 and a beta of 0.71. The business has a fifty day simple moving average of $98.98 and a two-hundred day simple moving average of $96.83. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.The firm had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same period in the previous year, the company posted $1.38 earnings per share. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).